{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:04:21Z","timestamp":1757617461817,"version":"3.44.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41574-025-01122-y","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:00:10Z","timestamp":1746097210000},"page":"510-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7958-128X","authenticated-orcid":false,"given":"Andrea","family":"Schelhaas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-0003","authenticated-orcid":false,"given":"Stephanie","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"1122_CR1","unstructured":"BioMarin. BioMarin Pharmaceutical third quarter 2024 conference call. BioMarin https:\/\/investors.biomarin.com\/events-and-presentations\/event-details\/2024\/BioMarin-Pharmaceutical-Third-Quarter-2024-Conference-Call\/default.aspx (2024)."},{"key":"1122_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01074-9","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan, R. et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat. Rev. Endocrinol. https:\/\/doi.org\/10.1038\/s41574-024-01074-9 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1122_CR3","unstructured":"Little People of America. LPA\u2019s position statement regarding BioMarin\u2019s Voxzogo. Little People of America. https:\/\/www.lpaonline.org\/voxzogo-position-statement (2022)."},{"key":"1122_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gim.2024.101274","volume":"26","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan, R. et al. Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life. Genet. Med. 26, 12 (2024).","journal-title":"Genet. Med."},{"key":"1122_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1477-7525-11-76","volume":"11","author":"M Bullinger","year":"2013","unstructured":"Bullinger, M. et al. Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument. Health Qual. Life Outcomes 11, 76 (2013).","journal-title":"Health Qual. Life Outcomes"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01122-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:59:56Z","timestamp":1757134796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01122-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1038\/s41574-025-01122-y","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"type":"print","value":"1759-5029"},{"type":"electronic","value":"1759-5037"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"1 May 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. is a genetic counsellor with achondroplasia, a parent of children with achondroplasia and a member of the Little People of America Medical Advisory Board. A.S. has received consulting fees from both BioMarin and Tyra BioSciences. A.S. received remuneration from various genetic counselling training programmes and non-profit genetics societies including the National Society of Genetic Counselors and the American College of Medical Genetics to speak on issues related to skeletal dysplasia and\/or disability, ableism and ethics within genetics. K.A. is a board member for the Osteogenesis Imperfecta Foundation and also has osteogenesis imperfecta. K.A. serves on the Board of Governors for the Patient Centered Outcomes Research Institute. S.M. is the parent of an adult with Down syndrome and serves on the advisory board of the National Down Syndrome Congress and the National Down Syndrome Advocacy Coalition in a volunteer capacity. S.M. has received remuneration from the National Council on Disability, the Trisomy Collaborative, Down syndrome non-profit organizations, and non-profit medical and genetics organizations and programmes (National Society of Genetic Counselors, American College of Osteopathic Obstetricians and Gynecologists, American College of Medical Genetics and Genomics, and American Society of Human Genetics) for speaking engagements and associated travel expenses. L.S. is a co-facilitator for Her Power, Her Pride and also has achondroplasia. K.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}